ArticleThe journal of headache and pain2025
Small-molecule CGRP antagonist atogepant does not affect cortical spreading depression susceptibility in rats.
Article in The journal of headache and pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- A delayed endothelial-glial mechanism for CGRP-induced migraine.The journal of headache and pain · 2026Review
- Cerebrospinal Fluid and Plasma Concentrations of Atogepant in Humans.Clinical and translational science · 2026Article
- Article
- Is canonical SD a clinically relevant model of migraine? Argument con.The journal of headache and pain · 2025Review
- Abnormal neurovascular coupling induces glymphatic dysfunction in a mouse model of familial hemiplegic migraine type 2.The journal of headache and pain · 2025Article
- Intravital calcium imaging of meningeal macrophages reveals niche-specific dynamics and aberrant responses to brain hyperexcitability.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAtogepant is a small-molecule non-competitive calcitonin gene-related peptide (CGRP) receptor antagonist efficacious in preventing episodic migraine. Cortical spreading depolarization (CSD) is a slowly propagating depolarization wave underlying migraine aura. We investigated whether the efficacy of atogepant in migraine is mediated by CSD suppression.
methodWe used Sprague-Dawley rats (n = 28 males, 28 females) to determine the electrical stimulation intensity threshold for CSD induction and the frequency of CSDs induced by continuous topical 1 M KCl application sequentially in the same animal, using intracortical glass microelectrodes under isoflurane anesthesia and full systemic physiological monitoring, including arterial blood pressure and blood gases. In a separate cohort, we disrupted the BBB by inducing three CSDs in the contralateral hemisphere using 1 M KCl daily for 2 days before CSD susceptibility testing. Both cohorts received atogepant (30 mg/kg, once daily oral gavage) or vehicle for four days. CSD susceptibility was examined 1 h after the last atogepant dose.
resultsAtogepant did not affect the CSD threshold, frequency, propagation speed, amplitude, or duration compared with vehicle, either without or with preceding CSDs. Systemic physiological parameters did not differ between groups.
conclusionsThese data suggest that atogepant efficacy in migraine is not mediated via CSD suppression, even when BBB permeability is increased.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.